Detect Cancer Early

A better understanding of cancer biology along with advances in screening and targeted and immune therapies are transforming the ways in which we prevent, diagnose, treat, and ultimately survive cancer. Despite this, cancer continues as one of the leading causes of death globally. Around ~50% of cancers are diagnosed only after diagnosis of symptoms that indicate an advanced stage of disease, when treatment options are limited, and prognosis is poor.

Early cancer detection is a key determinant of patient outcomes, and current technology emphasizes circulating tumor DNA and circulating tumor cells. Further developments in new technologies and multiomic strategies will be needed for actionable insights into cancer biology and improved targeted treatments. The potential exists for circulatory plasma protein biomarkers to enable early cancer detection.

Download the application note to learn the opportunity with circulatory plasma protein biomarkers in three main aspects:

Circulating tumor DNA (ctDNA) combined with protein biomarkers increases accuracy of detection
Pathophysiology of ctDNA release is incomplete and protein biomarkers can illuminate this process
Pre-cancer diagnosis samples from longitudinal health assessments offer novel discovery

We will look at several recent examples where proteomics has made crucial contributions in cancer early detection:

Circulatory plasma protein biomarkers enable early cancer detection.
Olink Proteomics identifies pancreatic cancer risk factors from longitudinal population studies
Olink Proteomics identifies biomarker signatures for early detection of ovarian cancer

Download the application note: "How proteomics enriches the early detection of cancer"